Amyloidosis: open trials in United Kingdom

19 open trials have a site in United Kingdom. Registry data; only the trial team decides who can take part.

NCT06128629
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Intellia Therapeutics
Synexus Midlands Clinical Research Centre, Birmingham · Synexus Wales Clinical Research Centre, Cardiff · Synexus Scotland Clinical Research Centre, Glasgow · Synexus Hexham Clinical Research Centre, Hexham · Synexus Merseyside Clinical Research Centre, Liverpool · Richmond Pharmacology, London · Synexus Manchester Clinical Research Centre, Manchester
Registry updated 2026-11-04
NCT06978660
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Research · Idoven 1903 S.L.
Queen Elizabeth University Hospital, Univeisity of Glasgow, Glasgow
Registry updated 2026-11-04
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
University College Hospital, London · Royal Marsden Hospital, Sutton
Registry updated 2026-11-03
NCT07224672
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Trial Treatment · Phase 2 · GlaxoSmithKline
Liverpool · London
Registry updated 2026-11-03
NCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Bellshill · Birmingham · Cardiff · Hexham · London · Manchester
Registry updated 2026-10-21
NCT07207811
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Trial Treatment · Phase 3 · Novo Nordisk A/S
Synexus Scotland Clinical Research Centre, Bellshill · Synexus Midlands Clinical Research Centre, Birmingham · Synexus Wales Clinical Research Centre, Cardiff · Synexus Merseyside Clinical Research Centre, Liverpool · Richmond Pharmacology - MHRA Phase 1 Unit, London · The Royal Free Hospital - Royal Free London NHS Foundation Trust, London · Synexus Manchester Clinical Research Centre, Manchester
Registry updated 2026-10-21
NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
Bellshill · Birmingham · Cardiff · London · Manchester
Registry updated 2026-10-20
NCT07223203
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Trial Treatment · Phase 3 · Alnylam Pharmaceuticals
London
Registry updated 2026-10-08
NCT07235462
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Research · Bayer
Many Locations, Multiple Locations
Registry updated 2026-10-08
NCT06465810
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Research · AstraZeneca
Birmingham · Glasgow · London
Registry updated 2026-09-23
NCT07654855
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Research · AstraZeneca
Birmingham
Registry updated 2026-09-14
NCT06355934
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Research · AstraZeneca
London
Registry updated 2026-09-09
NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
University College London Hospitals, London · The Christie NHS Foundation Trust, Manchester
Registry updated 2026-08-18
NCT06563895
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Trial Treatment · Phase 3 · Eidos Therapeutics, a BridgeBio company
University College London Hospitals NHS Foundation Trust, London · St. Bartholomew's Hospital, London
Registry updated 2026-08-04
NCT05697861
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Research · Phase 2/3 · Intellia Therapeutics
London
Registry updated 2026-08-03
NCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Trial Treatment · Phase 1/2 · Alexion Pharmaceuticals, Inc.
London
Registry updated 2026-07-02
NCT05098665
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
Trial Treatment · Richmond Research Institute
Richmond Research Institute, London
Registry updated 2026-06-16
NCT05667493
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Trial Treatment · Phase 3 · Ionis Pharmaceuticals, Inc.
AES - Synexus - Scotland Clinical Research Centre, Bellshill · AES - Synexus - Wales, Cardiff · AES - Synexus - Midlands, Edgbaston · Royal Free London NHS Foundation Trust, Hampstead · Synexus Merseyside Clinical Research Centre, Liverpool · Richmond Pharmacology, London · Synexus Manchester Clinical Research Centre, Manchester · Synexus - Merseyside Clinical Research Centre, Manchester
Registry updated 2026-04-17
NCT06065852
National Registry of Rare Kidney Diseases
Research · UK Kidney Association
Zoe Plummer, Bristol
Registry updated 2023-10-04

All Amyloidosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error